

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Böx 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/004,867	12/07/2001	Serge Beaudoin	004208.00034	9077
22907 759	90 11/19/2003	EXAMINER		NER
BANNER & WITCOFF 1001 G STREET N W SUITE 1100 WASHINGTON, DC 20001			TRUONG, TAMTHOM NGO	
			ART UNIT	PAPER NUMBER
			1624	\bigcap
·			DATE MAILED: 11/19/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

`						
	Application No.	Applicant(s)				
Office Action Cumment	10/004,867	BEAUDOIN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Tamthom N. Truong	1624				
The MAILING DATE of this communication appears n the c ver sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the malling date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on 25 Au	igust 2003.					
2a) This action is FINAL . 2b) ⊠ This a	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-22 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-3, 5-9, 11, 13, and 14</u> is/are reject	ed.					
7) Claim(s) <u>4, 10, 12, and 15-21</u> is/are objected	d to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) acce	•					
Applicant may not request that any objection to the c						
Replacement drawing sheet(s) including the correcti	· · · · · · · · · · · · · · · · · · ·	• • • • • • • • • • • • • • • • • • • •				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 						
Attachment(s)	. 🗖					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 7. 		(PTO-413) Paper No(s) atent Application (PTO-152)				



Application/Control Number: 10/004,867

Art Unit: 1624

DETAILED ACTION

Applicant's amendment of 8-25-03 has been considered. The amended claims and argument have overcome the previous rejections of 112/1st and 2nd paragraph by deleting "prodrug". However, the argument has not overcome the 112/1st paragraph for spiro-cycle. Thus, said rejection is maintained herein. Furthermore, it is noted that claim 22 does not have adequate description, and enablement. Therefore, the following rejection is presented.

Claims 1-22 are still pending.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Lack of Written Description (for spiro-cycle): Claims 1-3, 5-9, 11, 13, and 14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Said claims allow for a spiro-cycle when R⁵ and R⁶ form a ring. However, the specification does not have a description for the arrangement of atoms, especially when such a ring is a heterocyclic spiro-cycle.



Application/Control Number: 10/004,867

Art Unit: 1624

- 2. Lack of Enablement (for spiro-cycle): Claims 1-3, 5-9, 11, 13, and 14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Despite applicant's argument, the fact remains that the specification does not provide any enablement for making a spiro-cycle, especially a heterocyclic one. Thus, one skilled in the art would still have to carry out undue experimentation for making such a spiro-cyclic system.
- 3. Lack of Written Description (for "cell proliferative disorder"): Claim 22 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 22 recites a "method for treating a cell proliferative disorder", which does not appear to have a description in term of what disorder is referred. If cell proliferative disorder means cancer or tumor, then the specification does not seem to specify which cancer or tumor.
- 4. Lack of Enablement (for "cell proliferative disorder"): Claim 22 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Since it is not known what disorder is meant by the phrase "cell"



Application/Control Number: 10/004,867

Art Unit: 1624

proliferative disorder", one skilled in the art cannot practice the claimed method without undue experimentation.

Claim Objections

5. Claims 4, 10, 12, and 15-21 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior arts of record do not teach compounds of formula (I) having R² as a substituted pyridyl ring.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (7 am -12 pm, and 3 pm - 6 pm) starting from 10-1st -03.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

T. Truong

November 17, 2003

ALAN L. ROTMAN

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Man L Rotman